Press release - 30/10/2012 DKFZ and Genetic Immunity Sign Collaboration Agreement to Develop HPV Therapeutic Vaccine Genetic Immunity, Budapest, a leader in immunotherapy technology product development, and DKFZ (German Cancer Research Center, Heidelberg, Germany) signed a collaborative agreement to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical cancer and other cancers of the anus, penis, vulva, vagina, and oropharynx. Present HPV vaccines (Cervarix, Gardasil) have no therapeutic effect on…https://www.gesundheitsindustrie-bw.de/en/article/press-release/dkfz-and-genetic-immunity-sign-collaboration-agreement-to-develop-hpv-therapeutic-vaccine
Press release - 19/10/2009 New ulcerative colitis therapy in sight Lipid Therapeutics GmbH and Dr. Falk Pharma GmbH announced on 30th, September, that they have entered into a co-development and licensing agreement for LT-02. Under the terms of the agreement, Dr. Falk Pharma will receive exclusive access to the European rights to Lipid Therapeutics’ lead product LT-02 for the treatment of ulcerative colitis. Ulcerative colitis is a severe inflammation of the colon affecting more than one million people…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-ulcerative-colitis-therapy-in-sight
Article - 20/10/2014 First ever eye gene therapy close to clinical testing There are many different retinal diseases simply because many different steps of the visual process can be affected. However, they all have one thing in common: correction of the relevant defective gene currently provides the only possibility of permanent cure. Prof. Dr. Mathias Seeliger and his group of researchers at the Institute of Ophthalmic Research at the University Hospital in Tübingen is specifically focused on the development of gene…https://www.gesundheitsindustrie-bw.de/en/article/news/first-ever-eye-gene-therapy-close-to-clinical-testing
Press release - 13/11/2009 Single molecules under the laser: How the genetic material is unwrapped The genetic material found in cells is not in its free state, but is bound to large protein complexes and tightly wrapped. To activate genes that could well play a role in carcinogenesis, the genetic material first needs to be unwrapped and made accessible to other cell components. Using a new biophysical method called single molecule spectroscopy, scientists from the “Biophysics of Macromolecules” division at the German Cancer Research Centre…https://www.gesundheitsindustrie-bw.de/en/article/press-release/single-molecules-under-the-laser-how-the-genetic-material-is-unwrapped
Press release - 12/08/2010 Glycotope Received Regulatory Approval for Glycooptimized and Fully Human Glycosylated Antibody CetuGEX™ and Enrolls First Patients in Clinical Trial Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX™ (GT-MAB 5.2-GEX) for the treatment of various solid cancers. https://www.gesundheitsindustrie-bw.de/en/article/press-release/glycotope-received-regulatory-approval-for-glycooptimized-and-fully-human-glycosylated-antibody-cetu
Article - 31/03/2014 TherapySelect – Identifying Susceptibility to Cancer Therapy TherapySelect Dr. Frank Kischkel is an innovative biotechnology company based in Heidelberg, Germany, with a special focus on the development, validation and application of diagnostic tests for cancer patients. The company’s proprietary CTR-Test® uses patients’ cancer cells to determine the tumor’s susceptibility to treatment with cytostatic drugs. This knowledge helps identify ineffective drugs prior to treatment as well as reduce adverse drug…https://www.gesundheitsindustrie-bw.de/en/article/news/therapyselect-identifying-susceptibility-to-cancer-therapy
Press release - 15/07/2014 amcure Receives EUR 5 Million Funding for the Development of New Tumour Therapeutic Agents amcure GmbH, a spin-off from the Karlsruhe Institute of Technology (KIT), has closed a Series A financing deal amounting to a total of EUR 5 million. The funding comes from a consortium headed by LBBW Venture Capital, with participations from KfW, MBG Mittelständische Beteiligungsgesellschaft Baden-Wuerttemberg, S-Kap Beteiligungen Pforzheim, BioM AG as well as private investors. The company also receives subsidies from the German Ministry of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/amcure-receives-eur-5-million-funding-for-the-development-of-new-tumour-therapeutic-agents
Alternative to animal experiments - 21/03/2018 Drug tests using miniature organs At present, potential new drugs have to be tested on animals before they can be used on humans. However, results obtained from animals are not always transferrable to the situation in humans, which is why researchers around the world have long been seeking alternatives. Miniature human organs that can be used to test the efficacy of potential human drugs might provide a solution.https://www.gesundheitsindustrie-bw.de/en/article/news/drug-tests-using-miniature-organs
Press release - 15/04/2010 Nycomed and Baxter receive FDA approval for TachoSil® Today Nycomed and its partner Baxter International Inc. NYSE BAX received the approval for TachoSil a surgical patch from the US Food and Drug Administration FDA. TachoSil has been approved as an adjunct to haemostasis control of bleeding in cardiovascular surgery. https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-and-baxter-receive-fda-approval-for-tachosil
Company profile - 31/07/2018 Acousia Therapeutics: medicines for deafness Deafness is one of the most common sensory disorders in the world: in Germany alone, around eleven million people suffer from hearing loss. So far there is no real therapy, the symptoms can only be alleviated to a greater or lesser degree. This is what researchers from the Tübingen-based company Acousia Therapeutics want to change: they have identified drug candidates that can protect sensory hair cells and support their function.https://www.gesundheitsindustrie-bw.de/en/article/news/acousia-therapeutics-medicines-for-deafness
Press release - 05/11/2014 Orphan drug status for Synovo's immune modulator SYD003 The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to Synovo's investigational compound SYD003, a first in class tumour-targeted immune modulator.https://www.gesundheitsindustrie-bw.de/en/article/press-release/orphan-drug-status-for-synovo-s-immune-modulator-syd003
Article - 16/06/2014 Methadone – the last step to becoming an anti-cancer drug It all began several years ago with a surprising discovery in the laboratory. Claudia Friesen, a chemist at Ulm University, discovered that leukaemia cells that were exposed to methadone died within a relatively short period of time. Seven years on and many papers later, what was once a rather exotic substance is now undergoing clinical testing in cancer patients.https://www.gesundheitsindustrie-bw.de/en/article/news/methadone-the-last-step-to-becoming-an-anti-cancer-drug
Company profile - 27/06/2016 Atriva Therapeutics GmbH: new ways to treat influenza Influenza viruses constantly change and mutate. This makes treatment difficult and vaccination rather touch and go. But what about targeting virus-manipulated cell events rather than using the virus itself as drug target? Atriva Therapeutics GmbH, a start-up company from Tübingen, shows how this works.https://www.gesundheitsindustrie-bw.de/en/article/news/atriva-therapeutics-gmbh-new-ways-to-treat-influenza
Press release - 14/07/2016 Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines CureVac AG, the most clinically advanced mRNA company, today announced that a study of its RNActive® technology was published in the renowned, peer-reviewed journal Vaccine. The study demonstrated a mechanistic insight into the mode of action and rationale for the use of messenger RNA (mRNA) for the development of multiple vaccines.https://www.gesundheitsindustrie-bw.de/en/article/press-release/study-in-peer-reviewed-journal-vaccine-demonstrates-decoding-mode-of-action-of-mrna-vaccines
Press release - 07/10/2020 Joining forces against SARS-CoV-2 Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech.https://www.gesundheitsindustrie-bw.de/en/article/press-release/joining-forces-against-sars-cov-2
Press release - 14/03/2022 Do gut bacteria influence treatment success of CAR-T cell therapies? Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
Press release - 18/02/2010 New molecules promise improved diagnosis of pancreatic cancer Being diagnosed with pancreatic cancer is often a death sentence. One reason for the high mortality rate of pancreatic cancer patients is that there is currently no reliable diagnosis of early stages and no cure once the disease has reached a late stage. In an EU-funded project, 23 research groups from six countries have developed new strategies for the improved diagnosis of pancreatic cancer. Researchers at the Ulm-based Hospital for Nuclear…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecules-promise-improved-diagnosis-of-pancreatic-cancer
Press release - 21/09/2021 Antibiotic levels measurable in breath for first time A team of engineers and biotechnologists at the University of Freiburg has for the first time shown in mammals that the concentration of antibiotics in the body can be determined using breath samples. The breath measurements also corresponded to the antibiotic concentrations in the blood. The team’s biosensor – a multiplex chip – will in future enable personalized dosing of medicines against infectious diseases on-site.https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibiotic-levels-measurable-breath-first-time
Press release - 01/04/2022 FDA approval for targeted radioligand therapy for treatment of metastatic prostate cancer On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.https://www.gesundheitsindustrie-bw.de/en/article/press-release/fda-approval-targeted-radioligand-therapy-treatment-metastatic-prostate-cancer
Press release - 28/07/2009 New trachea made from human tissue A team of doctors from the Schillerhöhe Hospital, which is part of the Robert Bosch Hospital in Stuttgart, in cooperation with researchers from the Fraunhofer Institute of Interfacial Engineering and Biotechnology IGB in Stuttgart, has developed a method that enables artificially produced autologous tissue to be implanted into patients with severe tracheal injuries. The method involves the cultivation of extensive parts of the human trachea and…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-trachea-made-from-human-tissue
Press release - 12/12/2016 Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-obtains-eib-debt-financing-totaling-up-to-eur-25-million-to-further-expand-its-diagnostic-platform
Article - 30/05/2011 Technology Licensing Office (TLB): invention and patent management The Technology Licensing Office TLB works in partnership with science and industry and is continuously coming up with new ways to ensure the economic success of inventions from all the key fields of technology. Dr. Frank Schlotter head of Life Sciences at the Karlsruhe-based TLB provides insights into the work that his office does taking as examples innovations from the fields of regenerative medicine and diagnostics.https://www.gesundheitsindustrie-bw.de/en/article/news/technology-licensing-office-tlb-invention-and-patent-management
Article - 30/08/2010 More effective prevention and treatment of diabetic feet Dr. med. dent. Hans-Helmut Schmidt has developed a device that enables the effective and hygienic treatment of patients with diabetic foot syndrome DFS. The new device known as DIAPEDES enables diabetic feet to be treated in a closed foot-shaped container under definite clinical conditions. Diabetic feet can smell and look quite unpleasant and the preventive care that this device will offer for many users has been developed with this problem in…https://www.gesundheitsindustrie-bw.de/en/article/news/more-effective-prevention-and-treatment-of-diabetic-feet
Article - 11/03/2013 PHAST GmbH: firm focus on growth strategy Since August last year, PHAST Development GmbH & Co. KG has been bringing a breath of fresh air to the old research campus of the pharmaceutical company Takeda (formerly Nycomed) in Konstanz. The pharmaceutical company, with its roots in the city of Homburg, Germany, is a specialist in innovative methods for testing the quality of medicines. Amongst other things, PHAST develops test methods that enable the optimisation of drug release. A…https://www.gesundheitsindustrie-bw.de/en/article/news/phast-gmbh-firm-focus-on-growth-strategy